Cardiff Oncology, Inc. CRDF
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -71.70%
- 1 year
- -64.65%
- Market cap
- 61.87M
- Revenue (ttm)
- 688.00K
- EPS (ttm)
- -0.60
- Shares out
- 66.52M
- Forward P/E
- -4.03
- YTD return
- -71.70%
- 1-year return
- -64.65%
- Volume
- 349.38K
- Avg volume
- 636.39K
- Open
- 0.798
- Previous close
- 0.7553
- Day's range
- 0.7601 – 0.798
- 52-week range
- 0.76 – 3.21
- Beta
- 1.93
- Analysts
- Strong Buy
- Price target
- 10.75 (+1251.7%)
MAX -1,640.8047 (-99.95%)
Key statistics
- Enterprise value
- 161.85M
- PEG ratio
- 0.00
- Price / sales
- 393.54
- Price / book
- 4.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 17.00%
- Free cash flow
- -19.85M
- Total cash
- 57.67M
- Total debt
- 1.69M
- Return on equity
- -67.57%
- Short % of float
- 16.40%
- 50-day average
- 3.08
- 200-day average
- 3.20
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 10.75
- Target (high)
- 13.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.24667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Aug 8, 2024 | Jun 1, 2024 | -0.25 | -0.26 | -0.01 | -4.00% |
| May 2, 2024 | Mar 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Feb 29, 2024 | Dec 1, 2023 | -0.26 | -0.21 | +0.05 | +19.23% |
| Nov 2, 2023 | Sep 1, 2023 | -0.29 | -0.22 | +0.07 | +24.14% |
| Aug 9, 2023 | Jun 1, 2023 | -0.27 | -0.25 | +0.02 | +7.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 6, 2024 | Craig-Hallum | init | — | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 1, 2024 | Piper Sandler | main | Overweight | Overweight |
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cardiffoncology.com
News
Cardiff Oncology to Participate in the UBS Global Biopharma Conference 
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June 
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2 
Cardiff Oncology Announces Presentation Of Phase 2 Trial Data For RAS-Mutated mCRC Treatment Onvansertib At ASCO Annual Meeting On June 2
Your note
Sign in to keep a note on CRDF — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ERLANDER MARK | Officer | Conversion of Exercise of derivative security | Jan 1, 2020 | 6,376 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.35% | 2,735,581 | 11.13M | Sep 29, 2024 |
| Vanguard Group Inc | 4.25% | 2,171,444 | 8.84M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.82% | 928,232 | 3.78M | Sep 29, 2024 |
| State Street Corporation | 1.63% | 832,652 | 3.39M | Sep 29, 2024 |
| MAI Capital Management | 1.30% | 663,363 | 2.70M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.18% | 602,384 | 2.45M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.45% | 1,254,717 | 5.11M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 956,644 | 3.89M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 600,175 | 2.44M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.79% | 404,508 | 1.65M | Aug 30, 2024 |
| College Retirement Equities Fund-Stock Account | 0.56% | 284,650 | 1.16M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 244,669 | 995.80K | Oct 30, 2024 |